Prostate cancer is one of the most common malignancies in males. The biggest challenge in treating the disease is drug resistance. Our latest paper identifies a nodal cancer-promoting protein , CIP2A,
as a common functional effector to both androgen receptor (AR) signalling and Cancer Stem-Like cells.
ROLE OF CIP2A IN CLINICALLY CHALLENGING PROSTATE CANCER
as a common functional effector to both androgen receptor (AR) signalling and Cancer Stem-Like cells.
ROLE OF CIP2A IN CLINICALLY CHALLENGING PROSTATE CANCER
No comments:
Post a Comment